摘要
在西方国家,心血管疾病(CVD)是死亡、慢性疾病和残疾的主要原因。心血管疾病最常见的原因是急性心肌缺血和随后的再灌注损伤的有害影响。“调节协议”使对急性缺血/再灌注损伤心脏的保护作用成为可能。调节应用于一段时间的短暂缺血和在长期(指数)缺血再灌注导致的心机梗死。同时前和后调节刺激分别在局部缺血发生前和后产生。前和后调节刺激可以应用在不同的/远隔器官(前处理和后处理);在这种情况下调节刺激应用于指标,所谓的远隔预调节。所有这些内源性保护措施补充了内生细胞保护剂和引起心血管通路的特定因素。在这里,我们讨论他们的主要特征和机制。重点在于是否给内源性保护剂或表面受体,包括嗜铬粒蛋白A的衍生物、生长素相关的肽、生长因子和细胞因子、微泡和外来体。此外综述了一氧化氮、硫化氢和一氧化碳对心血管的影响。这些知识为将来可能的转化医学提供依据。
关键词: 心肌保护,嗜铬粒蛋白A的衍生物,胞外体,生长素相关的肽,GPCR活化剂,生长因子,缺血/再灌注损伤,酪氨酸激酶激活物
Current Drug Targets
Title:Endogenous Cardioprotective Agents: Role in Pre and Postconditioning
Volume: 16 Issue: 8
Author(s): Claudia Penna, Riccarda Granata, Carlo Gabriele Tocchetti, Maria Pia Gallo, Giuseppe Alloatti and Pasquale Pagliaro
Affiliation:
关键词: 心肌保护,嗜铬粒蛋白A的衍生物,胞外体,生长素相关的肽,GPCR活化剂,生长因子,缺血/再灌注损伤,酪氨酸激酶激活物
摘要: Cardiovascular diseases (CVD) are the leading cause of death, chronic illness and disability in Western countries. The most common cause of CVD derives from the harmful effects of acute myocardial ischemia and subsequent reperfusion injury. Cardioprotection against acute ischemia/ reperfusion injury is made possible by the "conditioning protocols." Conditioning is obtained by applying a few periods of brief ischemia and reperfusion in the event of prolonged (index) ischemia that may cause myocardial infarction. Whilst the conditioning stimulus is applied before the index ischemia in ischemic pre-conditioning, it is applied after the event in post-conditioning. Pre and post- conditioning stimuli can be applied in a different/remote organ (remote pre- and post-conditioning); in this case conditioning stimulus can also be applied during the index event, in the so called remote per-conditioning. All these endogenous cardioprotective strategies recruit endogenous cytoprotective agents and factors that elicit specific cardioprotective pathways. Here, we discuss many of these cardioprotective factors compared to literature and highlight their main characteristics and mechanisms of action. Enphasis is given to endogenous cardioprotective agents acting or not on surface receptors, including chromogranin A derivatives, ghrelin-associated peptides, growth factors and cytokines, and to microvesicles and exosomes. Moreover the cardioprotective effects of gasotransmitters nitric oxide, hydrogen sulphide and carbon monoxide are reviewed. The possible clinical translation of these knowledge for future successful therapies is briefly and critically discussed.
Export Options
About this article
Cite this article as:
Claudia Penna, Riccarda Granata, Carlo Gabriele Tocchetti, Maria Pia Gallo, Giuseppe Alloatti and Pasquale Pagliaro , Endogenous Cardioprotective Agents: Role in Pre and Postconditioning, Current Drug Targets 2015; 16 (8) . https://dx.doi.org/10.2174/1389450116666150309115536
DOI https://dx.doi.org/10.2174/1389450116666150309115536 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus: An Update on Recent Developments
Current Diabetes Reviews The Coronary Collateral Circulation in Man
Current Cardiology Reviews Epigenetic Modulation: A Promising Avenue to Advance Hematopoietic Stem Cell-Based Therapy for Severe Autoimmune Disorders
Epigenetic Diagnosis & Therapy (Discontinued) Acute Stroke Therapy: Combination Drugs and Multifunctional Neuroprotectants
Current Neuropharmacology What Fans the Fire: Insights into Mechanisms of Leptin in Metabolic Syndrome- Associated Heart Diseases
Current Pharmaceutical Design Consequences of Iron Accumulation in Microglia and its Implications in Neuropathological Conditions
CNS & Neurological Disorders - Drug Targets Transient Cerebral Ischemia Leads to TGF-β2 Expression in Golgi Apparatus Organelles
Current Neurovascular Research 2015 Update of Erectile Dysfunction Management Following Radical Prostatectomy: From Basic Research to Clinical Management
Current Pharmaceutical Design Discovery of Lansoprazole and its Unique Pharmacological Properties Independent from Anti-secretory Activity
Current Pharmaceutical Design Augmentation Therapy with Alpha1-antitrypsin: Novel Perspectives
Cardiovascular & Hematological Disorders-Drug Targets Factors Affecting 30-Day Mortality in Chinese Patients with Acute Myocardial Infarction: A Registry-Based Cohort Study
Vascular Disease Prevention (Discontinued) Small Players With Big Roles: MicroRNAs as Targets to Inhibit Breast Cancer Progression
Current Drug Targets RNAi-Based Therapy in Experimental Ischemia-Reperfusion Injury. The New Targets
Current Pharmaceutical Design Targeting Drugs to APJ Receptor: The Prospect of Treatment of Hypertension and Other Cardiovascular Diseases
Current Drug Targets Adenosine Dysfunction in Epilepsy and Associated Comorbidities
Current Drug Targets Mechanisms of Endothelial Dysfunction: Clinical Significance and Preventive Non-Pharmacological Therapeutic Strategies
Current Pharmaceutical Design A Comprehensive Study of Pharmacological Behaviors, Nano-Formulations, and Applications of Rosemary
The Natural Products Journal Ex Vivo Liver – Directed Gene Therapy for the Treatment of Metabolic Diseases: Advances in Hepatocyte Transplantation and Retroviral Vectors
Current Gene Therapy Current Understanding of Polymyxin B Applications in Bacteraemia/ Sepsis Therapy Prevention: Clinical, Pharmaceutical, Structural and Mechanistic Aspects
Anti-Infective Agents in Medicinal Chemistry Energy Remodeling, Mitochondrial Disorder and Heart Failure
Current Pharmaceutical Design